PD-1/PD-L1 inhibitors prevent PD-L1 from binding to PD-1 on immune cells, relieving the inhibition of cancer immunosuppression and stimulating immune cells to attack cancer cells (Chen and Han, 2015; Postow et al., 2015; Sun et al., 2018; Andrews et al., 2019; Hayashi and Nakagawa, 2020). The gene discussed is CD274; the disease is cancer.